Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001013762-25-002278
Filing Date
2025-03-25
Accepted
2025-03-25 17:27:56
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 12359
  Complete submission text file 0001013762-25-002278.txt   14135
Mailing Address 121 RICHMOND STREET WEST PENTHOUSE SUITE 1300 TORONTO A6 M5H 2K1
Business Address 121 RICHMOND STREET WEST PENTHOUSE SUITE 1300 TORONTO A6 M5H 2K1 27744604171
PSYENCE BIOMEDICAL LTD. (Subject) CIK: 0001985062 (see all company filings)

EIN.: 000000000 | State of Incorp.: A6 | Fiscal Year End: 0331
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-94325 | Film No.: 25769430
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 121 RICHMOND STREET WEST PENTHOUSE SUITE, 1300 TORONTO A6 M5H 2K1
Business Address 121 RICHMOND STREET WEST PENTHOUSE SUITE, 1300 TORONTO A6 M5H 2K1 4163467764
Psyence Group Inc. (Filed by) CIK: 0002009573 (see all company filings)

EIN.: 000000000 | State of Incorp.: A6 | Fiscal Year End: 1231
Type: SCHEDULE 13D/A